SLC5A2 and kidney disorder: The UK Kidney Association Clinical Practice Guideline for Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease has provided comprehensive recommendations for SGLT2 inhibitor use, including consideration of sotagliflozin in specific patient populations.